Y650C
Category 4 — Stable Fold, Function DisruptedConflictingTransmembrane · predictedEditorialTyrosine → Cysteine at position 650 inside TM10. ClinVar Conflicting including Cataract 41 + DFNA6. AlphaMissense 0.399 (below threshold), ΔΔG +0.31. Third Atlas variant at position 650 (with Y650H, Y650D).
Interactive 3D Structure
Bond changes · DynaMut2 interaction analysis
| Interaction type | Wild-type partner | Mutant partner | Status |
|---|---|---|---|
| Hydrogen bond | I338 | — | Lost |
| Hydrogen bond | F646 | F646 | Preserved |
| Hydrogen bond | C647 | C647 | Preserved |
| Hydrogen bond | R653 | — | Lost |
| Hydrogen bond | S654 | S654 | Preserved |
| Polar contact | F646 | F646 | Preserved |
| Polar contact | C647 | C647 | Preserved |
| Polar contact | W648 | W648 | Preserved |
| Polar contact | Y652 | — | Lost |
| Polar contact | R653 | R653 | Preserved |
| Polar contact | S654 | S654 | Preserved |
| Van der Waals | — | F646 | Gained |
| Van der Waals | W648 | — | Lost |
Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.
Computational Predictions
- transmembrane position; predictor benchmarked on soluble proteins
- pLDDT 68.69 below 70
This variant sits in the transmembrane band. The stability value was computed with a predictor benchmarked on water-soluble proteins. Published benchmarks of ddG predictors on membrane proteins report correlation below 0.4. Treat the magnitude as unreliable and the sign as weak evidence only.
The underlying AlphaFold model has pLDDT below 70 at this position, so the structure the stability calculation was run on is itself uncertain.
Do not rank this value against a variant from a different region on ΔΔG alone.
Clinical Evidence
Observed at very low frequency in gnomAD.
ClinVar classifies this variant as Conflicting classifications of pathogenicity for Cataract 41 (autosomal dominant, OMIM 116400); Nonsyndromic hearing loss (DFNA6/14/38) (autosomal dominant, OMIM 600965); Wolfram syndrome (classic) (autosomal recessive, OMIM 222300); WFS1-related diabetes (autosomal dominant); Wolfram-like syndrome (autosomal dominant, OMIM 614296). These are two clinically distinct disease families: classic Wolfram syndrome requires two affected copies, while the dominant WFS1-related disorders do not. One label covers both, and it does not tell you which applies to a given person.
- Cataract 41autosomal dominant · OMIM 116400submitted as: Cataract 41
- Nonsyndromic hearing loss (DFNA6/14/38)autosomal dominant · OMIM 600965submitted as: Autosomal dominant nonsyndromic hearing loss 6
- Wolfram syndrome (classic)autosomal recessive · OMIM 222300submitted as: Wolfram syndrome 1
- WFS1-related diabetesautosomal dominantsubmitted as: Type 2 diabetes mellitus
- Wolfram-like syndromeautosomal dominant · OMIM 614296submitted as: Wolfram-like syndrome
- Submitters conflict on this classification (1★). Treat the conditions above as submitted, not as documented phenotypes.
- Phenotype scope is interpretation of submitted records. The computed values on this card (AlphaMissense, DynaMut2 ΔΔG, pLDDT) are measurements of the model, not of a patient.
- Presentation cannot be generalised from neighbouring variants: one nucleotide over can present very differently. Structural similarity supports a mechanistic hypothesis, never a phenotype claim.
Review status: 1★ conflicting classifications. ClinVar "conditions" is the union of all submissions; 0–1★ entries are submitted conditions, not documented phenotypes.
Highest in East Asian: AF 0.016% (7 of 44,864 alleles), 3.7x the global figure. The global AF describes the general population, not the at-risk group.
No homozygotes reported in gnomAD v4. For a recessive allele this is expected and is not, on its own, evidence either way.
| Ancestry group | Allele freq. | AC / AN | Hom. | Carrier est. |
|---|---|---|---|---|
| East Asian | 0.016% | 7 / 44,864 | 0 | ~1 in 3200 |
| European (non-Finnish) | 0.0047% | 55 / 1,180,000 | 0 | ~1 in 10730 |
| Ashkenazi Jewish · under-sampled | 0.0034% | 1 / 29,606 | 0 | — |
| African / African American | 0.0027% | 2 / 74,894 | 0 | ~1 in 18720 |
| South Asian | 0.0022% | 2 / 91,078 | 0 | ~1 in 22770 |
| Admixed American · under-sampled | 0.0017% | 1 / 59,996 | 0 | — |
Source: gnomAD r4, retrieved 2026-08-21. Values are allele frequencies. The carrier estimate is derived from the allele frequency (Hardy-Weinberg, ~2·AF) and is an approximation, not a published figure — where a published carrier frequency exists it outranks this column and is cited on the card.
Structural Context
Position 650 same neighbors as Y650H/Y650D: PHE649 (2.5 Å), VAL651 (2.5 Å), CYS647 (3.7 Å — C647 already in close contact!), PHE646 (3.7 Å). The C647 contact suggests a potential Y650C-C647 disulfide formation.
Y650C is the THIRD substitution at position 650. The new C650 could potentially form a disulfide with C647 (3.7 Å away) — possibly a beneficial or aberrant chemistry depending on the wild-type C647 state. Compare with Y650H (preserved aromatic) and Y650D (charge introduction).
AM 0.399 below threshold; multi-phenotype confirms.
Druggability Assessment
Mechanism: aromatic loss + potential aberrant disulfide with C647. Therapeutic: same Y650 microregion as Y650H/Y650D.
Why this matters
Feed this card to Wolfram Intelligence
Download the Y650C PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.